Belgian pharmaceutical firm UCB has entered the immunodermatology field in the U.S. market.
Treatments for Plaque Psoriasis
Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.
The TNF alpha inhibitor certolizumab pegol has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis, shows a study published in JAAD.
Brodalumab most cost-effective with high efficacy for plaque psoriasis, but IL-17 inhibitors as a whole outperform other biologics, study shows.
Twice-monthly certolizumab for plaque psoriasis could prove to be an option for patients who struggle with twice-weekly dosing, a study shows.
A study that compares the safety, efficacy and drug survival of biologics to biosimilars, finds that switching to a biosimilar had no significant impact on drug survival or safe
While there are biologics and systemic agents designed to control the severe form of plaque psoriasis, few treatments work as well in moderate plaque psoriasis. Apremilast may be a game changer.
Acute or irregular flushing may signal a more serious health condition, say researchers who list 14 questions physicians should ask patients complaining about unusual flushing.
A small study shows that ultrasound may be a viable diagnostic tool to determine whether patients have psoriasis or psoriatic arthritis, Italian researchers report.
A JAMA Dermatology study raises the possibility of adopting the NASH FibroSure test to detect hepatic fibrosis in psoriasis patients and minimize the number of liver biopsies.